nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxymorphone—CYP3A4—Cytarabine—lymphatic system cancer	0.0387	0.318	CbGbCtD
Oxymorphone—CYP3A4—Teniposide—lymphatic system cancer	0.0381	0.313	CbGbCtD
Oxymorphone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0266	0.219	CbGbCtD
Oxymorphone—CYP3A4—Vincristine—lymphatic system cancer	0.0183	0.151	CbGbCtD
Oxymorphone—Sweating increased—Fludarabine—lymphatic system cancer	0.00647	0.00736	CcSEcCtD
Oxymorphone—Vertigo—Mechlorethamine—lymphatic system cancer	0.00641	0.0073	CcSEcCtD
Oxymorphone—Disorientation—Bleomycin—lymphatic system cancer	0.00629	0.00717	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00603	0.00687	CcSEcCtD
Oxymorphone—Pneumonia—Fludarabine—lymphatic system cancer	0.00595	0.00678	CcSEcCtD
Oxymorphone—Mental disability—Carmustine—lymphatic system cancer	0.00588	0.00669	CcSEcCtD
Oxymorphone—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00566	0.00644	CcSEcCtD
Oxymorphone—Flushing—Teniposide—lymphatic system cancer	0.00561	0.00639	CcSEcCtD
Oxymorphone—Anorexia—Mechlorethamine—lymphatic system cancer	0.00555	0.00632	CcSEcCtD
Oxymorphone—Amnesia—Carmustine—lymphatic system cancer	0.00523	0.00596	CcSEcCtD
Oxymorphone—Visual impairment—Fludarabine—lymphatic system cancer	0.00512	0.00583	CcSEcCtD
Oxymorphone—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00506	0.00577	CcSEcCtD
Oxymorphone—Diplopia—Carmustine—lymphatic system cancer	0.00491	0.0056	CcSEcCtD
Oxymorphone—Agitation—Teniposide—lymphatic system cancer	0.00484	0.00551	CcSEcCtD
Oxymorphone—Bronchospasm—Bleomycin—lymphatic system cancer	0.00479	0.00545	CcSEcCtD
Oxymorphone—Malnutrition—Fludarabine—lymphatic system cancer	0.00462	0.00527	CcSEcCtD
Oxymorphone—Hypertension—Teniposide—lymphatic system cancer	0.00454	0.00517	CcSEcCtD
Oxymorphone—Chest pain—Teniposide—lymphatic system cancer	0.00448	0.0051	CcSEcCtD
Oxymorphone—Urinary retention—Vincristine—lymphatic system cancer	0.00446	0.00508	CcSEcCtD
Oxymorphone—Lung disorder—Methotrexate—lymphatic system cancer	0.00443	0.00504	CcSEcCtD
Oxymorphone—Weight decreased—Bleomycin—lymphatic system cancer	0.0044	0.00501	CcSEcCtD
Oxymorphone—Pneumonia—Bleomycin—lymphatic system cancer	0.00436	0.00497	CcSEcCtD
Oxymorphone—Dehydration—Vincristine—lymphatic system cancer	0.00436	0.00497	CcSEcCtD
Oxymorphone—Confusional state—Teniposide—lymphatic system cancer	0.00433	0.00493	CcSEcCtD
Oxymorphone—Oedema—Teniposide—lymphatic system cancer	0.00429	0.00489	CcSEcCtD
Oxymorphone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00429	0.00489	CcSEcCtD
Oxymorphone—Agitation—Fludarabine—lymphatic system cancer	0.00425	0.00484	CcSEcCtD
Oxymorphone—Dehydration—Mitoxantrone—lymphatic system cancer	0.00425	0.00484	CcSEcCtD
Oxymorphone—Tachycardia—Teniposide—lymphatic system cancer	0.00419	0.00477	CcSEcCtD
Oxymorphone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00415	0.00473	CcSEcCtD
Oxymorphone—Pruritus—Mechlorethamine—lymphatic system cancer	0.00412	0.00469	CcSEcCtD
Oxymorphone—Anorexia—Teniposide—lymphatic system cancer	0.00409	0.00466	CcSEcCtD
Oxymorphone—Hypotension—Teniposide—lymphatic system cancer	0.00401	0.00457	CcSEcCtD
Oxymorphone—Convulsion—Fludarabine—lymphatic system cancer	0.00401	0.00456	CcSEcCtD
Oxymorphone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00399	0.00454	CcSEcCtD
Oxymorphone—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00385	0.00438	CcSEcCtD
Oxymorphone—Dyspnoea—Teniposide—lymphatic system cancer	0.00383	0.00436	CcSEcCtD
Oxymorphone—Pneumonia—Carmustine—lymphatic system cancer	0.00381	0.00434	CcSEcCtD
Oxymorphone—Confusional state—Fludarabine—lymphatic system cancer	0.00381	0.00433	CcSEcCtD
Oxymorphone—Oedema—Fludarabine—lymphatic system cancer	0.00377	0.0043	CcSEcCtD
Oxymorphone—Decreased appetite—Teniposide—lymphatic system cancer	0.00373	0.00425	CcSEcCtD
Oxymorphone—Vomiting—Mechlorethamine—lymphatic system cancer	0.0037	0.00422	CcSEcCtD
Oxymorphone—Nervous system disorder—Fludarabine—lymphatic system cancer	0.0037	0.00421	CcSEcCtD
Oxymorphone—Apnoea—Methotrexate—lymphatic system cancer	0.0037	0.00421	CcSEcCtD
Oxymorphone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00367	0.00418	CcSEcCtD
Oxymorphone—Weight decreased—Vincristine—lymphatic system cancer	0.00367	0.00418	CcSEcCtD
Oxymorphone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00365	0.00415	CcSEcCtD
Oxymorphone—Pneumonia—Vincristine—lymphatic system cancer	0.00364	0.00414	CcSEcCtD
Oxymorphone—Flushing—Bleomycin—lymphatic system cancer	0.00361	0.00412	CcSEcCtD
Oxymorphone—Anorexia—Fludarabine—lymphatic system cancer	0.0036	0.0041	CcSEcCtD
Oxymorphone—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00357	0.00407	CcSEcCtD
Oxymorphone—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00354	0.00403	CcSEcCtD
Oxymorphone—Feeling abnormal—Teniposide—lymphatic system cancer	0.00354	0.00403	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00351	0.004	CcSEcCtD
Oxymorphone—Nausea—Mechlorethamine—lymphatic system cancer	0.00346	0.00394	CcSEcCtD
Oxymorphone—Urticaria—Teniposide—lymphatic system cancer	0.00341	0.00388	CcSEcCtD
Oxymorphone—Oliguria—Methotrexate—lymphatic system cancer	0.0034	0.00387	CcSEcCtD
Oxymorphone—Abdominal pain—Teniposide—lymphatic system cancer	0.00339	0.00387	CcSEcCtD
Oxymorphone—Body temperature increased—Teniposide—lymphatic system cancer	0.00339	0.00387	CcSEcCtD
Oxymorphone—Hallucination—Carmustine—lymphatic system cancer	0.00338	0.00385	CcSEcCtD
Oxymorphone—Dyspnoea—Fludarabine—lymphatic system cancer	0.00336	0.00383	CcSEcCtD
Oxymorphone—Dyspepsia—Fludarabine—lymphatic system cancer	0.00332	0.00378	CcSEcCtD
Oxymorphone—Decreased appetite—Fludarabine—lymphatic system cancer	0.00328	0.00374	CcSEcCtD
Oxymorphone—Visual impairment—Carmustine—lymphatic system cancer	0.00328	0.00373	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00326	0.00371	CcSEcCtD
Oxymorphone—Fatigue—Fludarabine—lymphatic system cancer	0.00325	0.00371	CcSEcCtD
Oxymorphone—Hallucination—Vincristine—lymphatic system cancer	0.00323	0.00368	CcSEcCtD
Oxymorphone—Pain—Fludarabine—lymphatic system cancer	0.00323	0.00368	CcSEcCtD
Oxymorphone—Constipation—Fludarabine—lymphatic system cancer	0.00323	0.00368	CcSEcCtD
Oxymorphone—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00322	0.00366	CcSEcCtD
Oxymorphone—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00321	0.00365	CcSEcCtD
Oxymorphone—Urethral disorder—Vincristine—lymphatic system cancer	0.00318	0.00362	CcSEcCtD
Oxymorphone—Eye disorder—Carmustine—lymphatic system cancer	0.00318	0.00362	CcSEcCtD
Oxymorphone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00316	0.0036	CcSEcCtD
Oxymorphone—Flushing—Carmustine—lymphatic system cancer	0.00316	0.00359	CcSEcCtD
Oxymorphone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00311	0.00354	CcSEcCtD
Oxymorphone—Asthenia—Teniposide—lymphatic system cancer	0.00308	0.00351	CcSEcCtD
Oxymorphone—Pruritus—Teniposide—lymphatic system cancer	0.00304	0.00346	CcSEcCtD
Oxymorphone—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00303	0.00345	CcSEcCtD
Oxymorphone—Cardiac disorder—Vincristine—lymphatic system cancer	0.00301	0.00343	CcSEcCtD
Oxymorphone—Body temperature increased—Fludarabine—lymphatic system cancer	0.00298	0.0034	CcSEcCtD
Oxymorphone—Mental disorder—Carmustine—lymphatic system cancer	0.00298	0.00339	CcSEcCtD
Oxymorphone—Malnutrition—Carmustine—lymphatic system cancer	0.00296	0.00337	CcSEcCtD
Oxymorphone—Angiopathy—Vincristine—lymphatic system cancer	0.00294	0.00335	CcSEcCtD
Oxymorphone—Diarrhoea—Teniposide—lymphatic system cancer	0.00294	0.00335	CcSEcCtD
Oxymorphone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00293	0.00333	CcSEcCtD
Oxymorphone—Chest pain—Bleomycin—lymphatic system cancer	0.00289	0.00329	CcSEcCtD
Oxymorphone—Mental disorder—Vincristine—lymphatic system cancer	0.00284	0.00324	CcSEcCtD
Oxymorphone—Confusional state—Bleomycin—lymphatic system cancer	0.00279	0.00318	CcSEcCtD
Oxymorphone—Vision blurred—Carmustine—lymphatic system cancer	0.00279	0.00318	CcSEcCtD
Oxymorphone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00278	0.00317	CcSEcCtD
Oxymorphone—Oedema—Bleomycin—lymphatic system cancer	0.00277	0.00315	CcSEcCtD
Oxymorphone—Vomiting—Teniposide—lymphatic system cancer	0.00273	0.00311	CcSEcCtD
Oxymorphone—Agitation—Carmustine—lymphatic system cancer	0.00272	0.0031	CcSEcCtD
Oxymorphone—Asthenia—Fludarabine—lymphatic system cancer	0.00271	0.00308	CcSEcCtD
Oxymorphone—Dermatitis—Teniposide—lymphatic system cancer	0.00271	0.00308	CcSEcCtD
Oxymorphone—Headache—Teniposide—lymphatic system cancer	0.00269	0.00306	CcSEcCtD
Oxymorphone—Pruritus—Fludarabine—lymphatic system cancer	0.00267	0.00304	CcSEcCtD
Oxymorphone—Anorexia—Bleomycin—lymphatic system cancer	0.00264	0.003	CcSEcCtD
Oxymorphone—Agitation—Vincristine—lymphatic system cancer	0.0026	0.00296	CcSEcCtD
Oxymorphone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00259	0.00295	CcSEcCtD
Oxymorphone—Hypotension—Bleomycin—lymphatic system cancer	0.00259	0.00294	CcSEcCtD
Oxymorphone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00258	0.00294	CcSEcCtD
Oxymorphone—Convulsion—Carmustine—lymphatic system cancer	0.00256	0.00292	CcSEcCtD
Oxymorphone—Hypertension—Carmustine—lymphatic system cancer	0.00256	0.00291	CcSEcCtD
Oxymorphone—Nausea—Teniposide—lymphatic system cancer	0.00255	0.0029	CcSEcCtD
Oxymorphone—Vertigo—Vincristine—lymphatic system cancer	0.00254	0.00289	CcSEcCtD
Oxymorphone—Chest pain—Carmustine—lymphatic system cancer	0.00252	0.00287	CcSEcCtD
Oxymorphone—Anxiety—Carmustine—lymphatic system cancer	0.00251	0.00286	CcSEcCtD
Oxymorphone—Dyspnoea—Bleomycin—lymphatic system cancer	0.00247	0.00281	CcSEcCtD
Oxymorphone—Convulsion—Vincristine—lymphatic system cancer	0.00245	0.00279	CcSEcCtD
Oxymorphone—Hypertension—Vincristine—lymphatic system cancer	0.00244	0.00278	CcSEcCtD
Oxymorphone—Confusional state—Carmustine—lymphatic system cancer	0.00244	0.00277	CcSEcCtD
Oxymorphone—Oedema—Carmustine—lymphatic system cancer	0.00242	0.00275	CcSEcCtD
Oxymorphone—Decreased appetite—Bleomycin—lymphatic system cancer	0.00241	0.00274	CcSEcCtD
Oxymorphone—Visual disturbance—Methotrexate—lymphatic system cancer	0.0024	0.00274	CcSEcCtD
Oxymorphone—Vomiting—Fludarabine—lymphatic system cancer	0.0024	0.00273	CcSEcCtD
Oxymorphone—Convulsion—Mitoxantrone—lymphatic system cancer	0.00238	0.00271	CcSEcCtD
Oxymorphone—Dermatitis—Fludarabine—lymphatic system cancer	0.00238	0.00271	CcSEcCtD
Oxymorphone—Hypertension—Mitoxantrone—lymphatic system cancer	0.00238	0.0027	CcSEcCtD
Oxymorphone—Pain—Bleomycin—lymphatic system cancer	0.00237	0.00269	CcSEcCtD
Oxymorphone—Headache—Fludarabine—lymphatic system cancer	0.00236	0.00269	CcSEcCtD
Oxymorphone—Tachycardia—Carmustine—lymphatic system cancer	0.00236	0.00268	CcSEcCtD
Oxymorphone—Chest pain—Mitoxantrone—lymphatic system cancer	0.00234	0.00267	CcSEcCtD
Oxymorphone—Anxiety—Mitoxantrone—lymphatic system cancer	0.00233	0.00266	CcSEcCtD
Oxymorphone—Lethargy—Methotrexate—lymphatic system cancer	0.00232	0.00265	CcSEcCtD
Oxymorphone—Oedema—Vincristine—lymphatic system cancer	0.00231	0.00263	CcSEcCtD
Oxymorphone—Anorexia—Carmustine—lymphatic system cancer	0.0023	0.00262	CcSEcCtD
Oxymorphone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00228	0.0026	CcSEcCtD
Oxymorphone—Confusional state—Mitoxantrone—lymphatic system cancer	0.00226	0.00258	CcSEcCtD
Oxymorphone—Nervous system disorder—Vincristine—lymphatic system cancer	0.00226	0.00257	CcSEcCtD
Oxymorphone—Hypotension—Carmustine—lymphatic system cancer	0.00226	0.00257	CcSEcCtD
Oxymorphone—Oedema—Mitoxantrone—lymphatic system cancer	0.00225	0.00256	CcSEcCtD
Oxymorphone—Nausea—Fludarabine—lymphatic system cancer	0.00224	0.00255	CcSEcCtD
Oxymorphone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00223	0.00254	CcSEcCtD
Oxymorphone—Shock—Mitoxantrone—lymphatic system cancer	0.00221	0.00252	CcSEcCtD
Oxymorphone—Urticaria—Bleomycin—lymphatic system cancer	0.0022	0.0025	CcSEcCtD
Oxymorphone—Anorexia—Vincristine—lymphatic system cancer	0.0022	0.0025	CcSEcCtD
Oxymorphone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00219	0.0025	CcSEcCtD
Oxymorphone—Body temperature increased—Bleomycin—lymphatic system cancer	0.00219	0.00249	CcSEcCtD
Oxymorphone—Insomnia—Carmustine—lymphatic system cancer	0.00218	0.00249	CcSEcCtD
Oxymorphone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00218	0.00248	CcSEcCtD
Oxymorphone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00217	0.00247	CcSEcCtD
Oxymorphone—Hypotension—Vincristine—lymphatic system cancer	0.00215	0.00245	CcSEcCtD
Oxymorphone—Dyspnoea—Carmustine—lymphatic system cancer	0.00215	0.00245	CcSEcCtD
Oxymorphone—Somnolence—Carmustine—lymphatic system cancer	0.00215	0.00245	CcSEcCtD
Oxymorphone—Anorexia—Mitoxantrone—lymphatic system cancer	0.00214	0.00244	CcSEcCtD
Oxymorphone—Decreased appetite—Carmustine—lymphatic system cancer	0.0021	0.00239	CcSEcCtD
Oxymorphone—Hypotension—Mitoxantrone—lymphatic system cancer	0.0021	0.00239	CcSEcCtD
Oxymorphone—Insomnia—Vincristine—lymphatic system cancer	0.00209	0.00237	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00209	0.00237	CcSEcCtD
Oxymorphone—Constipation—Carmustine—lymphatic system cancer	0.00207	0.00235	CcSEcCtD
Oxymorphone—Pain—Carmustine—lymphatic system cancer	0.00207	0.00235	CcSEcCtD
Oxymorphone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00204	0.00232	CcSEcCtD
Oxymorphone—Decreased appetite—Vincristine—lymphatic system cancer	0.002	0.00228	CcSEcCtD
Oxymorphone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.002	0.00228	CcSEcCtD
Oxymorphone—Somnolence—Mitoxantrone—lymphatic system cancer	0.002	0.00227	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00199	0.00227	CcSEcCtD
Oxymorphone—Feeling abnormal—Carmustine—lymphatic system cancer	0.00199	0.00227	CcSEcCtD
Oxymorphone—Fatigue—Vincristine—lymphatic system cancer	0.00199	0.00226	CcSEcCtD
Oxymorphone—Asthenia—Bleomycin—lymphatic system cancer	0.00199	0.00226	CcSEcCtD
Oxymorphone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00198	0.00225	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00198	0.00225	CcSEcCtD
Oxymorphone—Pain—Vincristine—lymphatic system cancer	0.00197	0.00225	CcSEcCtD
Oxymorphone—Constipation—Vincristine—lymphatic system cancer	0.00197	0.00225	CcSEcCtD
Oxymorphone—Pruritus—Bleomycin—lymphatic system cancer	0.00196	0.00223	CcSEcCtD
Oxymorphone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00195	0.00222	CcSEcCtD
Oxymorphone—Fatigue—Mitoxantrone—lymphatic system cancer	0.00194	0.0022	CcSEcCtD
Oxymorphone—Pain—Mitoxantrone—lymphatic system cancer	0.00192	0.00219	CcSEcCtD
Oxymorphone—Constipation—Mitoxantrone—lymphatic system cancer	0.00192	0.00219	CcSEcCtD
Oxymorphone—Abdominal pain—Carmustine—lymphatic system cancer	0.00191	0.00217	CcSEcCtD
Oxymorphone—Body temperature increased—Carmustine—lymphatic system cancer	0.00191	0.00217	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00189	0.00215	CcSEcCtD
Oxymorphone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00185	0.00211	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00184	0.00209	CcSEcCtD
Oxymorphone—Abdominal pain—Vincristine—lymphatic system cancer	0.00182	0.00208	CcSEcCtD
Oxymorphone—Body temperature increased—Vincristine—lymphatic system cancer	0.00182	0.00208	CcSEcCtD
Oxymorphone—Urticaria—Mitoxantrone—lymphatic system cancer	0.00178	0.00203	CcSEcCtD
Oxymorphone—Hypersensitivity—Carmustine—lymphatic system cancer	0.00178	0.00203	CcSEcCtD
Oxymorphone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00178	0.00202	CcSEcCtD
Oxymorphone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00178	0.00202	CcSEcCtD
Oxymorphone—Pneumonia—Methotrexate—lymphatic system cancer	0.00176	0.00201	CcSEcCtD
Oxymorphone—Vomiting—Bleomycin—lymphatic system cancer	0.00176	0.002	CcSEcCtD
Oxymorphone—Dermatitis—Bleomycin—lymphatic system cancer	0.00174	0.00198	CcSEcCtD
Oxymorphone—Asthenia—Carmustine—lymphatic system cancer	0.00173	0.00197	CcSEcCtD
Oxymorphone—Hypersensitivity—Vincristine—lymphatic system cancer	0.0017	0.00193	CcSEcCtD
Oxymorphone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00165	0.00188	CcSEcCtD
Oxymorphone—Asthenia—Vincristine—lymphatic system cancer	0.00165	0.00188	CcSEcCtD
Oxymorphone—Diarrhoea—Carmustine—lymphatic system cancer	0.00165	0.00188	CcSEcCtD
Oxymorphone—Nausea—Bleomycin—lymphatic system cancer	0.00164	0.00187	CcSEcCtD
Oxymorphone—Asthenia—Mitoxantrone—lymphatic system cancer	0.00161	0.00183	CcSEcCtD
Oxymorphone—Dizziness—Carmustine—lymphatic system cancer	0.0016	0.00182	CcSEcCtD
Oxymorphone—Diarrhoea—Vincristine—lymphatic system cancer	0.00158	0.0018	CcSEcCtD
Oxymorphone—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00156	0.00177	CcSEcCtD
Oxymorphone—Urethral disorder—Methotrexate—lymphatic system cancer	0.00154	0.00176	CcSEcCtD
Oxymorphone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00154	0.00175	CcSEcCtD
Oxymorphone—Vomiting—Carmustine—lymphatic system cancer	0.00154	0.00175	CcSEcCtD
Oxymorphone—Dizziness—Vincristine—lymphatic system cancer	0.00152	0.00174	CcSEcCtD
Oxymorphone—Dermatitis—Carmustine—lymphatic system cancer	0.00152	0.00173	CcSEcCtD
Oxymorphone—Visual impairment—Methotrexate—lymphatic system cancer	0.00152	0.00173	CcSEcCtD
Oxymorphone—Headache—Carmustine—lymphatic system cancer	0.00151	0.00172	CcSEcCtD
Oxymorphone—Eye disorder—Methotrexate—lymphatic system cancer	0.00147	0.00168	CcSEcCtD
Oxymorphone—Vomiting—Vincristine—lymphatic system cancer	0.00147	0.00167	CcSEcCtD
Oxymorphone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00146	0.00166	CcSEcCtD
Oxymorphone—Dermatitis—Vincristine—lymphatic system cancer	0.00145	0.00165	CcSEcCtD
Oxymorphone—Headache—Vincristine—lymphatic system cancer	0.00144	0.00164	CcSEcCtD
Oxymorphone—Nausea—Carmustine—lymphatic system cancer	0.00143	0.00163	CcSEcCtD
Oxymorphone—Angiopathy—Methotrexate—lymphatic system cancer	0.00143	0.00163	CcSEcCtD
Oxymorphone—Vomiting—Mitoxantrone—lymphatic system cancer	0.00143	0.00163	CcSEcCtD
Oxymorphone—Immune system disorder—Methotrexate—lymphatic system cancer	0.00142	0.00162	CcSEcCtD
Oxymorphone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00142	0.00162	CcSEcCtD
Oxymorphone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00141	0.00161	CcSEcCtD
Oxymorphone—Headache—Mitoxantrone—lymphatic system cancer	0.00141	0.0016	CcSEcCtD
Oxymorphone—Mental disorder—Methotrexate—lymphatic system cancer	0.00138	0.00157	CcSEcCtD
Oxymorphone—Malnutrition—Methotrexate—lymphatic system cancer	0.00137	0.00156	CcSEcCtD
Oxymorphone—Nausea—Vincristine—lymphatic system cancer	0.00137	0.00156	CcSEcCtD
Oxymorphone—Nausea—Mitoxantrone—lymphatic system cancer	0.00133	0.00152	CcSEcCtD
Oxymorphone—Vision blurred—Methotrexate—lymphatic system cancer	0.00129	0.00147	CcSEcCtD
Oxymorphone—Vertigo—Methotrexate—lymphatic system cancer	0.00123	0.0014	CcSEcCtD
Oxymorphone—Convulsion—Methotrexate—lymphatic system cancer	0.00119	0.00135	CcSEcCtD
Oxymorphone—Chest pain—Methotrexate—lymphatic system cancer	0.00117	0.00133	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00116	0.00132	CcSEcCtD
Oxymorphone—Confusional state—Methotrexate—lymphatic system cancer	0.00113	0.00128	CcSEcCtD
Oxymorphone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.0011	0.00125	CcSEcCtD
Oxymorphone—Skin disorder—Methotrexate—lymphatic system cancer	0.00109	0.00124	CcSEcCtD
Oxymorphone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00108	0.00123	CcSEcCtD
Oxymorphone—Anorexia—Methotrexate—lymphatic system cancer	0.00107	0.00121	CcSEcCtD
Oxymorphone—Hypotension—Methotrexate—lymphatic system cancer	0.00105	0.00119	CcSEcCtD
Oxymorphone—Insomnia—Methotrexate—lymphatic system cancer	0.00101	0.00115	CcSEcCtD
Oxymorphone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000997	0.00114	CcSEcCtD
Oxymorphone—Somnolence—Methotrexate—lymphatic system cancer	0.000995	0.00113	CcSEcCtD
Oxymorphone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000985	0.00112	CcSEcCtD
Oxymorphone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000973	0.00111	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000966	0.0011	CcSEcCtD
Oxymorphone—Fatigue—Methotrexate—lymphatic system cancer	0.000965	0.0011	CcSEcCtD
Oxymorphone—Pain—Methotrexate—lymphatic system cancer	0.000957	0.00109	CcSEcCtD
Oxymorphone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000922	0.00105	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000915	0.00104	CcSEcCtD
Oxymorphone—Urticaria—Methotrexate—lymphatic system cancer	0.000889	0.00101	CcSEcCtD
Oxymorphone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000884	0.00101	CcSEcCtD
Oxymorphone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000884	0.00101	CcSEcCtD
Oxymorphone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000824	0.000939	CcSEcCtD
Oxymorphone—Asthenia—Methotrexate—lymphatic system cancer	0.000803	0.000914	CcSEcCtD
Oxymorphone—Pruritus—Methotrexate—lymphatic system cancer	0.000792	0.000901	CcSEcCtD
Oxymorphone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000766	0.000872	CcSEcCtD
Oxymorphone—Dizziness—Methotrexate—lymphatic system cancer	0.00074	0.000842	CcSEcCtD
Oxymorphone—Vomiting—Methotrexate—lymphatic system cancer	0.000711	0.00081	CcSEcCtD
Oxymorphone—Dermatitis—Methotrexate—lymphatic system cancer	0.000705	0.000803	CcSEcCtD
Oxymorphone—Headache—Methotrexate—lymphatic system cancer	0.000701	0.000798	CcSEcCtD
Oxymorphone—Nausea—Methotrexate—lymphatic system cancer	0.000665	0.000757	CcSEcCtD
